Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 4,2014,220 of 20,252 grants

Active NON-SBIR/STTR RPGS
Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms
NATIONAL CANCER INSTITUTE Research Inst of Fox Chase Can Ctr United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT The Ras/MAPK pathway is activated in 85% of human cancer. Nevertheless, attempts to target Ras/MAPK signaling have produced only limited efficacy. We hypot...

$6.72M
USD
Active NON-SBIR/STTR RPGS
The role of translation initiation factor eIF5B in lung cancer pathogenesis
NATIONAL CANCER INSTITUTE Ut Southwestern Medical Center United States 2023 – 2028

PROJECT SUMMARY Lung cancer cells express high levels of PD-L1, a ligand of the PD-1 receptor on T-cells, allowing tumors to directly suppress T cell activity. Anti-PD-1/PD-L1 anti...

$4.53M
USD
Completed NON-SBIR/STTR RPGS
Inhibition and Catalytic Degradation of Promutagenic DNA Deaminases
NATIONAL CANCER INSTITUTE University of Pennsylvania United States 2023 – 2025

PROJECT SUMMARY This proposal aims to develop the first potent and specific antagonists of the pro-mutagenic effects of APOBEC DNA deaminase enzymes in cells. Access to whole genom...

$2.17M
USD
Active NON-SBIR/STTR RPGS
The role of inflammation in the regulation of immune response in acute myeloid leukemia
NATIONAL CANCER INSTITUTE New York University School of Medicine United States 2023 – 2028

Project Summary/Abstract Survival outcomes of acute myeloid leukemia (AML) patients are negatively affected by high inflammation in the bone marrow compared to low inflammation pat...

$5.44M
USD
Active NON-SBIR/STTR RPGS
Evaluating an evidence-based family history screening program adapted to increase reach and uptake of screening for BRCA-associated cancers in rural public health clinics
NATIONAL CANCER INSTITUTE Emory University United States 2023 – 2028

PROJECT SUMMARY Brief and low-cost family history-based screening assessments to identify families at high risk for BRCA- associated cancers have been endorsed by national guidelin...

$5.73M
USD
Active SBIR-STTR RPGS
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer
NATIONAL CANCER INSTITUTE Pdx Pharmaceuticals, Inc United States 2023 – 2026

Lung cancer is the leading cause of cancer mortality, exceeding deaths from colon, breast, and prostate cancers combined. Resistance to chemo and targeted therapy is very common. R...

$9.14M
USD
Active NON-SBIR/STTR RPGS
Breast core-needle diagnostics in LMICs via millifluidics and direct-to-digital imaging: development and validation in Ghana
NATIONAL CANCER INSTITUTE University of California At Davis United States 2023 – 2028

ABSTRACT Breast cancer is an increasing challenge globally as it became the most prevalent malignancy at the end of 2020. More than 70% of all cancer mortality now occurs in low- a...

$6.42M
USD
Active NON-SBIR/STTR RPGS
Vitamin B6 Modulates NK Cell Metabolism in Pancreatic Cancer
NATIONAL CANCER INSTITUTE University of Oklahoma Hlth Sciences Ctr United States 2023 – 2028

Project Summary: The poor survival rates in pancreatic ductal adenocarcinoma patients are in part due to poor response to existing therapies. Thus, there is an urgent need to devel...

$3.99M
USD
Active NON-SBIR/STTR RPGS
Finding NEMO's Switchable MRI Signal Using Microfluidic Tumor Models
NATIONAL CANCER INSTITUTE West Virginia University United States 2023 – 2026

PROJECT SUMMARY Misdiagnosis is prevalent in younger women with dense breast tissue receiving breast cancer screening, resulting in missed cancers, needless follow-up testing, anxi...

$4.45M
USD
Active NON-SBIR/STTR RPGS
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2028

Project Summary & Abstract Adoptive T cell therapies (ACT) including chimeric antigen receptor (CAR) T cells are novel immunotherapies with unparalleled successes, especially i...

$5.96M
USD
Active NON-SBIR/STTR RPGS
Biomarker guided combinations for treating high-risk bladder cancer
NATIONAL CANCER INSTITUTE Augusta University United States 2023 – 2028

Bladder cancer (BC) is a common cancer of the urinary tract. While low-grade tumors have a good prognosis, two-thirds of patients with high-grade BC have tumors invading the bladde...

$5.57M
USD
Completed NON-SBIR/STTR RPGS
Optimizing CAR T therapy via metabolic engineering for thetreatment of GBM
NATIONAL CANCER INSTITUTE University of Florida United States 2023 – 2025

PROJECT SUMMARY AND ABSTRACT Significance: Glioblastoma (GBM) is an extremely devastating disease with reported median survivals ranging from 13 to 73 months and 5-year survivals o...

$1.78M
USD
Completed NON-SBIR/STTR RPGS
Selective Radionuclide Delivery for Precise Bone Marrow Niche Alterations
NATIONAL CANCER INSTITUTE Fred Hutchinson Cancer Center United States 2023 – 2025

PROJECT SUMMARY / ABSTRACT The bone marrow niche houses hematopoietic stem cells (HSCs), cells that self-renew and differentiate into vital blood components like white blood cells,...

$2.6M
USD
Completed NON-SBIR/STTR RPGS
Exposing the role of MYC in small cell carcinoma of the ovary hypercalcemic type
NATIONAL CANCER INSTITUTE Middle Tennessee State University United States 2023 – 2025

PROJECT SUMMARY/ABSTRACT SCCOHT is rare and often fatal ovarian cancer, with the average age of diagnosis being around 24-years old. The molecular pathogenesis of SCCOHT is overwhe...

$656.5K
USD
Active NON-SBIR/STTR RPGS
Exploration of different immunotherapy modalities in osteosarcoma
NATIONAL CANCER INSTITUTE Auburn University At Auburn United States 2023 – 2026

Project Summary/Abstract Osteosarcoma (OS) is the most common primary bone malignancy affecting long bones in children and the third most frequent in adults in the United States. T...

$4.41M
USD
Active RESEARCH CENTERS
University of Pennsylvania Patient-derived Xenograft Development and Trials Center
NATIONAL CANCER INSTITUTE University of Pennsylvania United States 2023 – 2028

Project Summary/Abstract: The overall goal of the University of Pennsylvania PDX Development and Therapeutics Center (UP-PDTC) is to (i) exploit the translational potential of PDX...

$9.31M
USD
Active RESEARCH CENTERS
University of Pennsylvania Patient-derived Xenograft Development and Trials Center
NATIONAL CANCER INSTITUTE University of Pennsylvania United States 2023 – 2028

Summary: The goal of the Administrative Core of the University of Pennsylvania PDX Development and Trials Center is primarily to facilitate innovative translational science that wi...

Active RESEARCH CENTERS
PDX Core
NATIONAL CANCER INSTITUTE University of Pennsylvania United States 2023 – 2028

Summary: The PDX Core of the UP-PDTC is the primary experimental laboratory of the extensive xenotransplantation program at the University of Pennsylvania (UPENN). Research into hu...

Active RESEARCH CENTERS
Bioinformatics Core
NATIONAL CANCER INSTITUTE University of Pennsylvania United States 2023 – 2028

Summary: The Bioinformatics Core is the primary data management and analysis arm of the UP-PDTC. Of note, the Bioinformatics Core will include biostatistics, bioinformatic and data...

Active RESEARCH CENTERS
Acute myeloid leukemia (AML) Research Project
NATIONAL CANCER INSTITUTE University of Pennsylvania United States 2023 – 2028

Summary Acute myeloid leukemia (AML) is one of the most intensely studied of human malignancies. In recent years there have been major advances in defining the molecular pathogenes...